[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Leblay et al., 2020 - Google Patents

Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities

Leblay et al., 2020

View HTML
Document ID
15195388779733655500
Author
Leblay N
Maity R
Hasan F
Neri P
Publication year
Publication venue
Frontiers in oncology

External Links

Snippet

Immunotherapy has recently emerged as a promising treatment option for multiple myeloma (MM) patients. Profound immune dysfunction and evasion of immune surveillance are known to characterize MM evolution and disease progression. Along with genomic changes …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Similar Documents

Publication Publication Date Title
Leblay et al. Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities
Vago et al. Immune escape and immunotherapy of acute myeloid leukemia
Jogalekar et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Yousefi et al. Immunotherapy of cancers comes of age
Beyar-Katz et al. Novel approaches to acute myeloid leukemia immunotherapy
Atanackovic et al. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
Kirkwood et al. Immunotherapy of cancer in 2012
Li et al. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Baxevanis et al. Cancer immunotherapy
Geller et al. Use of allogeneic NK cells for cancer immunotherapy
Bachireddy et al. Haematological malignancies: at the forefront of immunotherapeutic innovation
Wu et al. B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity
Kumar et al. Immune therapies in multiple myeloma
Przespolewski et al. Advances in immunotherapy for acute myeloid leukemia
Rodríguez-Otero et al. Is immunotherapy here to stay in multiple myeloma?
Yamamoto et al. Harnessing the immune system against multiple myeloma: challenges and opportunities
US11266689B2 (en) NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
Zuo et al. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers
Danylesko et al. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
Jung et al. Immunotherapy for the treatment of multiple myeloma
Yang et al. The progress and current status of immunotherapy in acute myeloid leukemia
Clara et al. Harnessing natural killer cells for the treatment of multiple myeloma
WO2016184592A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
Ji et al. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines